Asciminib is a novel tyrosine kinase inhibitor (TKI) that specifically targets the myristoyl pocket. It has increased selectivity and potent activity against BCR-ABL1 and the mutants that most frequently prevent the activity of the ATPbinding competitive inhibitors. Results for clinical trials in patients with chronic myeloid leukemia that have received two or more TKI (randomized aga... https://www.bekindtopets.com/save-now-Aqua-Pure-3MFF101-Full-Flow-Drinking-Water-System-Replacement-Cartridge-flash-choice/